Skip to content Skip to footer
VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024

Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots

Shots: G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data Philip further goes ahead to share details on VTAMA’s ongoing study…

Read more

Exclusive_Stacey Williams_2023

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots:Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasisThe “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatmentThe…

Read more

Exclusive Interview_Philip M. Brown_Dr. Anna Tallman

Philip Brown & Anna Tallman of Dermavant Shares Insights on the Approval of its Topical Treatment for Plaque Psoriasis

Shots:Philip spoke about plaque psoriasis, symptoms, prognosis, and treatment options available. He also discussed different ongoing patient support programs by DermavantAnna talked about the approval of Dermavant’s lead topical treatment in plaque psoriasis, its clinical studies & resultsThe interview summarizes Dermavant’s aim to develop innovative therapeutics in immuno-dermatology to address the high…

Read more